Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, developed by Eli Lilly for obesity and type 2 diabetes
J.CombsC
Water, Prunus Armeniaca (Apricot) Kernel Oil, Glycerin , Camellia Japonica Seed Oil, Niacinamide , Sodium Chloride, Butylene Glycol, Lonicera Japonica (Honeysuckle) Flower Extract, Cetearyl Alcohol, Propolis Extract , Oryza Sativa (Rice) Extract, 1,2-Hexanediol, Cetearyl Glucoside, Hydrogenated Lecithin, Caprylic/Capric Triglyceride, Ascorbic Acid (Vitamin C), Acorus Calamus Root Extract, Perilla Ocymoides Leaf Extract, Hydroxydecyl Ubiquinone , Glycine Soja (Soybean) Sterols, Citrus Aurantium Dulcis (Orange) Oil, Lavandula Angustifolia (Lavender) Oil, PPG-26-Buteth-26, Panthenol, Caprylyl Glycol, Aniba Rosaeodora (Rosewood) Wood Oil, Rosmarinus Officinalis (Rosemary) Leaf Oil, Foeniculum Vulgare (Fennel) Oil, Acetyl Hexapeptide-8, Copper Tripeptide-1, Palmitoyl Pentapeptide-4, Tripeptide-1, Palmitoyl Tripeptide-1, Hexapeptide-9, Nonapeptide-1 This formula is full of peptides - they all should help with wrinkles and skin condition
In the field of unimolecular polypharmacology, the placement of a massive lipid moiety runs the severe biophysical risk of inducing destructive steric clashes within the binding pockets of the target receptors, which would completely nullify receptor activation
